Seer, Inc. (SEER) - Earnings per share increase in current year

Seer, Inc. aims for leadership in proteomics through the implementation of the Proteograph system for rapid protein analysis. However, geopolitical risks and US trade barriers create long-term challenges. The annual earnings per share growth indicator on GURU.Markets reflects this balance, where the 15.70 metric captures the current trend. Steady demand from biotech laboratories is currently supporting the share price as AI solutions continue to evolve.

Seer, Inc. (SEER): Earnings growth in current year from 07/04/2022 to 11/14/2026

Financial and market metric breakdowns for Seer Inc (SEER)

- price and consensus price forecast:

Stock Quotes Seer, Inc.|SEER - Consensus Target

- market capitalization indicators:

Market Value Seer, Inc.|SEER - Total Company Value

- business book valuation details:

Accounting Value per Share Seer|SEER - Book Capitalization|Market-to-Book Ratio seer.bio|SEER - Company Total Assets

- debt and liquidity details:

- net income and valuation ratios data:

SEER - Net Income|Expected Net Income Seer, Inc.|SEER - P/E Multiple|Projected Price to Earnings Ratio seer.bio|SEER - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Multiple Seer Inc|SEER - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Seer|SEER - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months seer.bio|SEER - Earnings per share growth in current year|Net earnings per share change forecast for next year Seer, Inc.

- sales volume and revenue information:

SEER - Company Revenue|Company Future Sales Volume Seer Inc.|SEER - P/S Multiple|Market Cap to Future Revenue Ratio Seer, Inc.

Fundamental valuation:SEER, Seer Inc.

The indicator is calculated as the percentage deviation of current earnings per share from the value of the same period last year, reflecting the dynamics of the company's actual earnings. For Seer, Inc. (SEER), this metric demonstrates the extent to which strategic alliances in mass spectrometry and the development of the Proteograph platform convert into financial results, which is clearly captured by the annual EPS change scale.

Direct competitors